

ASX ANNOUNCEMENT

7 May 2026

2026 Annual Meeting of Stockholders Presentation of President & CEO

Sunnyvale, California; 7 May 2026: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), is pleased to provide the presentation of the President & CEO to be delivered at the Company’s virtual 2026 Annual Meeting of Stockholders today, Thursday, 7 May 2026 at 9.00am Australian Eastern Standard time (Wednesday, 6 May 2026 at 4.00pm U.S. Pacific Daylight time).

To attend the Annual Meeting, enter meetnow.global/M9UHQT7 into a web browser on your computer or online device:

- Stockholders will need to select “Stockholder” and enter their Shareholder Control Number which will have been provided by Computershare Investor Services; and
- CDI holders will need to select “Guest” and enter their name and email address (but may not vote at the meeting);
- Proxyholders will need to select “Invitation” and enter a proxy number which will have been provided by Computershare Investor Services

Further information in relation to the Annual Meeting is set out in the Notice of Annual Meeting of Stockholders released on 27 March 2026.

Attached are the AGM presentation slides.

ENDS

This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.

For more information, please contact:

Company

Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrwise.com

Investor Relations

Gabriella Hold
The Capital Network
P: +61 2 8999 3699
E: gaby@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems’ WiSE Technology

EBR SYSTEMS, INC. (ARBN 654 147 127)

480 Oakmead Parkway, Sunnyvale CA 94085 USA T: +1 408 720 1906 W: <https://ebrsystemsinc.com/>

For personal use only

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.




AGM Presentation

May 2026

Exceeded all 2025 Major Milestones

Proven track record of achieving major clinical, regulatory, and reimbursement milestones



Early Commercial Traction/KPIs


Limited market release starts with trained salespeople, who then engage physicians, followed by hospital contracting negotiations, leading to treated patients and revenue

Physician Engagement


→ Site Negotiation and Contracting

→ Patients Treated and Revenue


Physicians Trained



Purchasing Contracts Signed



Cases Completed



Early commercial traction reinforces that EBR has a repeatable sales model with significant demand from both patients and physicians

Investment Highlights

Listed on ASX (symbol EBR) since 2021 and SEC registrant since 2024

The future of CRT is leadless...EBR's WiSE System is the only device capable of providing fully leadless CRT

Significant Growth Potential



No direct competitors

WiSE System is complementary to other cardiac pacing devices, including leadless pacemakers. WiSE is the only leadless device that can pace the left ventricle for heart failure



Large market opportunity

Targeting an initial addressable market of US\$5.8bn in the US




FDA PMA approved

US FDA approval received 11 April 2025 supported by Breakthrough Device Designation and compelling clinical data



Premium reimbursement

CMS approval for both NTAP (inpatient) and TPT (outpatient) at contract price of US\$63,300.




Clear commercial strategy

Continued commercial traction during Limited Market Release (LMR) phase, initiated Q4'25. Executed by an experienced team with a track record of scaling early-stage technology



Manufacturing facilities in place

New facility under construction to support commercial growth and improved margins
Expect full transition to new facility by the end of H2 2026



AGM Q&A Session



Contact:

Company

Andrew Shute

Chief Corporate Development Officer

P: +44 7730 691421

E: info@ebrwise.com

Investors

Gabriella Hold

The Capital Network

P: +61 2 8999 3699

E: gaby@thecapitalnetwork.com.au

www.ebrsystemsinc.com